Short answer
MEDIFAST INC (MED) filed an 8-K current report with the SEC on May 26, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders), Item 7.01 (Regulation FD Disclosure). 2026 annual meeting held May 19, 2026.
MEDIFAST INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- 2026 annual meeting held May 19, 2026
- Stockholders approved the amended and restated 2012 Share Incentive Plan
- Approval supports continued equity-based compensation for directors and employees
Item 5.07 · Submission of Matters to a Vote of Security Holders
- All seven director nominees elected, with Scott Schlackman receiving strongest opposition: 795,603 against
- RSM US LLP appointment ratified for fiscal 2026, with 6,411,175 votes for
- Executive compensation approved advisory, though 637,173 votes opposed
- Amended 2012 Plan approved, with notable opposition of 1,442,997 votes against
Item 7.01 · Regulation FD Disclosure
- CEO succession: Mr. Johnson appointed Chief Executive Officer, replacing Daniel R. Chard
- Daniel R. Chard transitioning to non-executive Chairman
- Leadership change disclosed May 26, 2026, with press-release details in Exhibit 99.2
- CEO transition creates execution and strategy continuity considerations for investors
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MEDIFAST INC 8-K filings
Get the next MED 8-K as it lands
Follow MED for push alerts, or ask the research agent what this filing means.